Eli Lilly and Company Announces Expansion of San Diego Biotechnology Center
Strong Focus on New Research Collaborations; Up to 130 New Positions to Be Created.
INDIANAPOLIS, July 23, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today revealed plans to expand the Lilly Biotechnology Center located in San Diego, Calif. The expansion will effectively double Lilly's research presence in San Diego as the company seeks to develop new collaborations in one of the world's leading regions for drug research and development.
Set to be completed in 2016, the expansion will feature an additional 175,000 square feet of working space and is expected to generate up to 130 potential new job openings, yielding a 140 percent increase in the center's space and 70 percent increase in its staff.
"San Diego has been an important location for Lilly laboratories for more than a decade. The city is a global hub for biomedical research and talent, where collaboration between academic institutions and biotechnology thrives," said Thomas F. Bumol, Ph.D., senior vice president, biotechnology and immunology research at Lilly. "We want to build on our success in San Diego through expanded collaborations that ultimately allow us to bring better medicines to people faster than ever before."
Importantly, the space will allow for closer collaboration among Lilly experts in discovery chemistry and research technologies and biotechnology, which will help accelerate the discovery of new medicines within the company's core therapeutic areas, including immunology.
The expansion also signifies Lilly's investment in obtaining additional top scientific talent. Specifically, Lilly will be recruiting experts in drug discovery in the disciplines of biotechnology, chemistry and immunology and in immunological clinical development.
"The molecular discovery capabilities at the Lilly Biotechnology Center represent state of the art platforms to enable pharmaceutical innovation across the continuum of small and large molecules," said Alan D. Palkowitz, Ph.D., vice president, discovery chemistry research & technologies at Lilly. "The expanded investment will further Lilly's leadership in these core areas and catalyze future discoveries."
Lilly initially entered the San Diego area in 2004 by acquiring Applied Molecular Evolution, Inc., which now operates as a subsidiary of the company. The Lilly Biotechnology Center was officially established in 2009 and is located near the University of California, San Diego, among other prominent biomedical research institutions.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
